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Editors: Anton N. Sidawy and Bruce A. PerlerMidterm results of adjunctive neck therapies performed during elective
infrarenal aortic aneurysm repair
Jayer Chung, Matthew A. Corriere, Ross Milner, Karthikeshwar Kasirajan,
Atef Salam, Thomas F. Dodson, Elliott L. Chaikof, Ravi Kumar Veeraswamy
Objective: This study evaluated the durability of adjunctive endovascular
neck procedures, including aortic cuffs, Palmaz stents (Cordis, Miami Lakes,
Fla), and high-pressure balloon angioplasty, at managing intraoperative
proximal neck complications during endovascular aortic aneurysm repair
(EVAR).
Methods: This was a single-center retrospective review of EVARs. The
primary outcome variable studied was survival free of a graft-related event
(GRE). GRE was defined by the occurrence of one of the following: type I
endoleak, sac enlargement, aneurysm rupture, death, or procedure related
to the aortic neck. These outcome variables were assessed relative to the
preoperative anatomic neck variables (neck length, diameter, degree of
angulation, degree of circumferential thrombus, and presence of conicity),
procedural variables (manufacturing type of graft, use of a Palmaz stent),
and patient characteristics (age and presence of medical comorbidities).
Outcomes were assessed by t tests, Pearson c2, and Kaplan-Meier analysis,
when appropriate.
Results: A total of 174 EVARs performed between January 2005 and
December 2007 were evaluated. Fifty-six adjunctive procedures were per-
formed, with a 97% primary-assisted exclusion rate. Patients who received
an adjunctive therapy had similar freedom from a GRE compared with EVARs
that did not require adjunctive therapy (35.5  2.6 vs 34.8  1.5 months, P =
.31, log-rank test). Subset analysis identified a significant association
between Palmaz stent placement at the time of EVAR and decreased
freedom from GREs (hazard ratio, 2.87; 95% confidence interval, 1.21-
6.77; P = .02).
Conclusions: Midterm results suggest that adjunctive therapies to manage
intraoperative proximal neck complications do not compromise durability.
The subset of patients requiring aortic neck Palmaz stent placement at
the time of EVAR are among those at highest risk for subsequent GRE.First United States experience of the TX2 Pro-Form thoracic delivery
system
W. Anthony Lee, Tomas D. Martin, Philip J. Hess Jr, Thomas M. Beaver,
Charles T. Klodell
Objectives: Failure to conform to the arch (‘‘bird-beaking’’) can lead to
endoleak and graft collapse after thoracic endovascular aortic repair
(TEVAR). We report the first United States experience with the new TX2
Pro-Form (Cook Inc, Bloomington, Ind), a novel delivery system that became
commercially available in October 2009, designed to enhance circumferen-
tial apposition of the TX2 thoracic endograft to the arch.* Full articles available online at www.jvascsurg.org
1078e5884/$36.00
doi:10.1016/S1078-5884(10)00655-6Methods: This was a single-institution retrospective study. Endograft-to-
arch conformance was quantitatively analyzed using intraoperative angio-
grams of consecutive, reverse chronologic cohorts of TX2 Pro-Form, TX2
Z-Trak (prior delivery system; Cook), and Gore TAG (W.L. Gore and Assoc,
Flagstaff, Ariz). Only native aortic arch deployments in zones 2 and 3 were
included.
Results: During a 6-week period, 20 Pro-Form cases were performed, of
which 17 patients met inclusion criteria. These were compared with 17
Z-Trak and 17 TAG patients. Endografts were successfully delivered to their
intended proximal landing zones in all 51 patients. A higher proportion of
dissections were treated in the Z-Trak (65%) and TAG (76%) patients
(P = .03), but similar rates of zone 2/3 deployments (P = .30). Despite the
mean arch angle being greatest for the Pro-Form patients (90 vs 74 vs
71, P = .18), the mean separation between the leading endograft edge
and the aortic wall along the inner curvature of the arch was significantly
less (1.4 vs 4.1 vs 5.7 mm; P = .0002), with complete apposition achieved
in 65% of Pro-Form patients (18% Z-Trak, 6% TAG, P < .0001). This resulted
in the lowest reduction in aortic luminal diameter at the proximal landing
zone (5.5% vs 13.4% vs 19.3%; P = .0006) compared with Z-Trak and TAG.
Rates of type Ia endoleak were similar (P = .38).
Conclusions: The Pro-Form delivery system significantly improves endograft
conformation to the arch, resulting in minimum bird-beaking even in
severely angulated anatomies.Outcomes before and after initiation of an acute aortic treatment center
Mark G. Davies, Houssam K. Younes, Patricia W. Harris, Faisal Masud, Bryan
A. Croft, Michael J. Reardon, Alan B. Lumsden
Background: Acute aortic syndromes remain life-threatening. Time is of the
essence, as mortality rises with increasing time after the acute episode. The
aim of this report is to show changes in practice and outcomes after
the establishment of an acute aortic treatment center (AATC) to expedite
the care of acute aortic syndromes in a major metropolitan area with the
belief that ‘‘door to intervention time under 90 minutes’’ reduces mortality
and morbidity from acute aortic disease.
Methods: A database of patients admitted with acute aortic disease (Type A
and B aortic dissections, acute thoraco-abdominal aortic aneurysms, acute
and ruptured abdominal aortic aneurysms) for 1 year prior to initiation
(2007) and 1 year after initiation of the pathway (AATC) in 2008 was devel-
oped. Comorbidities were scored according to Society of Vascular Surgery
criteria. Anatomic and functional outcomes were determined and catego-
rized by Society of Vascular Surgery reporting criteria. Multivariate analysis
was performed for categorical outcomes and Cox proportional hazard
analyses for time-dependent outcomes.
Results: Six hundred twenty-one patients reported with aortic disease to
the cardiovascular services; 306 patients were considered to have acute
disease. When compared with the year before the AATC was instituted,
there was a 30% increase in the total number of admissions and a 25%
increase in acute pathology after setting up the AATC (P = .02). There
was a two-fold increase in thoracic aortic dissections admitted to the
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64% reduction in time to definitive therapy (526  557 vs 187  258
minutes, mean  SD pre-AATC vs AATC; P = .0001). Comorbidity scores
were equivalent between the two cohorts. Despite the increase in acuity,
mortality (4% vs 6%) and morbidity (41% vs 45%) rates were unchanged,
and there was a significant decrease in intensive care unit length of stay
(5 vs 4 days, pre-AATC cohort vs the AATC cohort), but total hospital
length of stay (11 vs 10 days) was unchanged. There was no correlation
between deaths within 30 days and length of stay in the intensive care
unit.
Conclusion: Establishment of a multidisciplinary AATC pathway was associ-
ated with a 30% increase in volume, 64% reduction in time to definitive treat-
ment, improved throughput with reduced intensive care unit time, and
maintained clinical efficacy despite an increase in acute admissions. These
results suggest the concept be further evaluated.Eight-year experience with carotid artery stenting for correction of
symptomatic and asymptomatic post-endarterectomy defects
Enrico Maria Marone, Giovanni Coppi, Yamume Tshomba, Roberto Chiesa
Background: Carotid endarterectomy (CEA) has been shown to be superior
to medical therapy alone in the prevention of stroke only if it can be safely
performed (ie, with a complication rate less than 3% in asymptomatic
patients and less than 6% in symptomatic patients). Technical defects are
the most common cause of neurological complications after CEA, and their
correction has traditionally been performed through standard surgical
techniques.
Methods: From 1999, we started to treat intimal flaps, dissection, or partial
thrombosis after CEA with carotid artery stenting (CAS). A retrospective
analysis of the operating room registry and of the registry of our Interven-
tional Cardiology laboratory was conducted in order to identify all the
patients that underwent stenting of the internal carotid artery after CEA
between January 2001 and June 2009.
Results: During the time period considered, 5012 CEA were performed at
our institution and a total of 34 patients (34/5012; 0.6%) were found to have
received carotid stenting after CEA, both for symptomatic and asymptom-
atic defects. Immediate technical success was obtained in all patients.
One major cerebrovascular adverse event (1/34; 3%) in the immediate peri-
operative period was recorded. At a mean follow-up of 18.6 months (range,
3-84 months; median, 12 months), we did not observe any neurological
symptoms related to the treated carotid artery, nor hemodynamic in-stent
restenosis. Long-term follow-up (ie, equal or greater than 4 years) was avail-
able for five patients: all patients remained event-free during the entire
period.
Conclusions: Our study adds to the assumption that CAS in post-CEA symp-
tomatic and asymptomatic patients is safe and technically feasible, and
represents a valid and quick alternative to standard surgical revision. Even
if in a small group of patients, long-term results seem promising.Important observations made managing carotid body tumors during
a 25-year experience
Allan J. Kruger, Philip J. Walker, Wallace J. Foster, Jason S. Jenkins, Nicholas
S. Boyne, Julie Jenkins
Objectives: Our objective was to assess the short-term and long-term
outcome for patients after carotid body tumor (CBT) resection and discuss
the potential pitfalls of the treatment.
Methods: An analysis was undertaken of all patients who underwent CBT
resection at Royal Brisbane and Women’s Hospital and Greenslopes Private
Hospital between 1982 and 2007. Primary tumor characteristics, surgical
technique, and outcomes were recorded and analyzed.
Results: A total of 49 consecutive CBT resections (2 recurrent tumors) were
carried out in 39 patients (26 women [56%]) who were a mean age of 49 years
(range, 17-75 years). A nontender neck mass was the presenting complaint in
85%, followed by screening in familial or contralateral tumors in 26%.
Familial cases occurred in 11 patients (28%). There were no operative
deaths. Complications occurred in 13 of the 49 operations (27%), predomi-
nantly temporary nerve palsies, and were more likely to occur in tumors
of large volume or in cases of removal of coexisting vagal tumors. Malignantdisease was present in seven cases (15%). All patients have been followed-up
postoperatively for a mean of 11 years (range, 2-26 years). Metachronous
paragangliomas have been discovered in six patients, all with familial
disease.
Conclusions: Early resection of carotid body tumors should be undertaken
while still small to minimize the risk of neural injury, which increases with
tumor size. In cases of bilateral CBT, we recommend that the smaller tumor
be resected first, before the staged resection of the larger contralateral
tumor. In familial or bilateral tumor cases, other synchronous and metachro-
nous paragangliomas should be excluded. Mandatory lifelong follow-up is
essential.Safety and efficacy of patient specific intramuscular injection of HGF
plasmid gene therapy on limb perfusion and wound healing in patients
with ischemic lower extremity ulceration: Results of the HGF-0205 trial
Richard J. Powell, Phillip Goodney, Farrell O. Mendelsohn, Elaine K. Moen,
Brian H. Annex
Objectives: We have previously reported the results of a dose-finding phase
II trial showing that HGF angiogenic gene therapy can increase TcPO2
compared with placebo in patients with critical limb ischemia (CLI). The
purpose of this randomized placebo controlled multi-center trial was to
further assess the safety and clinical efficacy of a modified HGF gene
delivery technique in patients with CLI and no revascularization options.
Methods: Patients with lower extremity ischemic tissue loss (Rutherford 5
and 6) received three sets of eight intramuscular injections every 2 weeks
of HGF plasmid under duplex ultrasound guidance. Injection locations were
individualized for each patient based on arteriographically defined vascular
anatomy. Primary safety end-point was incidence of adverse events (AE) or
serious adverse events (SAE). Clinical endpoints included change from base-
line in toe brachial index (TBI), rest pain assessment by a 10 cm visual
analogue scale (VAS) as well as wound healing, amputation, and survival at
3 and 6 months.
Results: Randomization ratio was 3:1 HGF (n = 21) vs placebo (n = 6). Mean
age was 76  2 years, with 56% male and 59% diabetic. There was no differ-
ence in demographics between groups. There was no difference in AEs or
SAEs, which consisted mostly of transient injection site discomfort, wors-
ening of CLI, and intercurrent illnesses. Change in TBI significantly improved
from baseline at 6 months in the HGF-treated group compared with placebo
(0.05  0.05 vs 0.17  0.04; P = .047). Change in VAS from baseline at 6
months was also significantly improved in the HGF treated group compared
with placebo (1.9  1.3 vs +0.06  0.2; P = .04). Complete ulcer healing at
12 months occurred in 31% of the HGF group and 0% of the placebo (P = .28)
There was no difference in major amputation of the treated limb (HGF 29%
vs placebo 33%) or mortality at 12 months (HGF 19% vs placebo 17%) between
groups.
Conclusion: HGF gene therapy using a patient vascular anatomy specific
delivery technique appears safe, maintained limb perfusion, and decreased
rest pain in patients with CLI compared with placebo. A larger study to
assess the efficacy of this therapy on more clinically relevant end points is
warranted.Cost-effectiveness of guidelines for insertion of inferior vena cava filters
in high-risk trauma patients
Emily L. Spangler, Ellen D. Dillavou, Kenneth J. Smith
Background: Inferior vena cava filters (IVCFs) can prevent pulmonary embo-
lism (PE); however, indications for use vary. The Eastern Association for the
Surgery of Trauma (EAST) 2002 guidelines suggest prophylactic IVCF use in
high-risk patients, but the American College of Chest Physicians (ACCP)
2008 guidelines do not. This analysis compares cost-effectiveness of prophy-
lactic vs therapeutic retrievable IVCF placement in high-risk trauma
patients.
Methods: Markov modeling was used to determine incremental cost-
effectiveness of these guidelines in dollars per quality-adjusted life-years
(QALYs) during hospitalization and long-term follow-up. Our population
was 46-year-old trauma patients at high risk for venous thromboembolism
(VTE) by EAST criteria to whom either the EAST (prophylactic IVCF) or
ACCP (no prophylactic IVCF) guidelines were applied. The analysis
Abstracts 825assumed the societal perspective over a lifetime. For base case and sensi-
tivity analyses, probabilities and utilities were obtained from published
literature and costs calculated from Centers for Medicare & Medicaid
Services fee schedules, the Healthcare Cost & Utilization Project data-
base, and Red Book wholesale drug prices for 2007. For data unavailable
from the literature, similarities to other populations were used to make
assumptions.
Results: In base case analysis, prophylactic IVCFs were more costly ($37,700
vs $37,300) and less effective (by 0.139 QALYs) than therapeutic IVCFs. In
sensitivity analysis, the EAST strategy of prophylactic filter placement would
become the preferred strategy in individuals never having a filter, with
either an annual probability of VTE of 9.6% (base case, 5.9%), or a very high
annual probability of anticoagulation complications of 24.3% (base case,
2.5%). The EAST strategy would also be favored if the annual probability of
venous insufficiency was <7.69% (base case, 13.9%) after filter removal or
<1.90% with a retained filter (base case, 14.1%). In initial hospitalization
only, EAST guidelines were more costly by $2988 and slightly more effective
by .0008 QALY, resulting in an incremental cost-effectiveness ratio of
$383,638/QALY.
Conclusions: Analysis suggests prophylactic IVC filters are not cost-effective
in high-risk trauma patients. The magnitude of this result is primarily depen-
dent on probabilities of long-term sequelae (venous thromboembolism,
bleeding complications). Even in the initial hospitalization, however,
prophylactic IVCF costs for the additional quality-adjusted life years gained
did not justify use.The middle-arm fistula as a valuable surgical approach in patients with
end-stage renal disease
Giuseppe Bonforte, Emanuela Rossi, Sara Auricchio, Daniela Pogliani,
Stefano Mangano, Salvatore Mandolfo, Franco Galli, Simonetta GenovesiBackground: American and European guidelines recommend the distal
radial-cephalic fistula (dRCF) as the first and best hemodialysis access in
patients with end-stage renal disease (ESRD). However, this kind of arterio-
venous fistula (AVF) shows a limited primary unassisted patency and
frequently needs surgical revisions or angiographic procedures, or both.
When dRCF is not feasible, guidelines suggest a proximal brachiocephalic
AVF. The middle-arm fistula (MAF), or autogenous forearm radial-median
direct access, has been suggested as a possible alternative approach. This
study evaluated MAF primary unassisted patency, the most frequent causes
of MAF failure, and the possible related factors.
Methods: Data on patients with a MAF placed from January 1991 until June
2008 were retrospectively collected. The probability of MAF failure overall
and by the main subgroups was estimated according to Kaplan-Meier with
Greenwood standard error (SE). Comparison of failure among different
subgroups was performed using the log rank test in univariate analyses. The
Cox regression model was used to investigate factors that independently
affected the overall hazard of failure and cause-specific hazard of thrombosis.
Results: At the end of follow-up, 14.0% of MAF failed (11.6% thrombosis,
1.7% stenosis, 0.7% failed maturation), and 44.2% of MAF were still working.
Cumulative probability of MAF unassisted primary patency after 4 years from
the creation was 79%. Univariate analyses highlighted that women (P = .019),
underweight patients (P = .010), and MAF implantation after starting hemo-
dialysis (P < .001) had a higher risk of MAF failure for any cause than men,
normal and overweight patients, and MAF implanted before starting hemodi-
alysis. Results of the Cox multivariate analysis for overall MAF failure
confirmed that only MAF implantation before starting hemodialysis is
a protective factor against any failure (P = .003), whereas female gender
(P = .016) was associated with an increase of the thrombosis hazard ratio
to 2.04 (95% confidence interval, 1.14-3.63).
Conclusion: Our data demonstrate that MAF has a good unassisted primary
patency and suggest that this kind of AVF could be a valuable alternative
surgical approach when dRCF is not feasible in ESRD patients.
